Delayed, Bloody CSF for Neonatal HSV PCR
A 4-day-old term neonate develops fever, lethargy, and a cluster of scalp vesicles. CSF is collected at 22:40 on Friday: 1.5 mL in a sterile tube, grossly bloody (RBC 52,000/microliter, WBC 40/microliter, protein 95 mg/dL, glucose 45 mg/dL). The tube sits in the specimen room at ambient temperature and is logged in Saturday at 16:20, 17.7 hours after collection. The laboratory's HSV-1/2 real-time PCR is validated on CSF with a limit of detection of 500 copies/mL and includes an internal control. The clinician calls to ask whether the specimen is still usable, because a negative result would allow acyclovir to be stopped.
1. Do you accept or reject the specimen? Justify your decision in terms of what the delay does and does not affect.
Read the worked answer
Accept and test, with a documented comment - do not reject.
HSV is a double-stranded DNA virus, and the target detected in CSF is largely cell-free viral DNA, which is substantially more robust than RNA. An 18-hour ambient hold is outside the ideal window and is a deviation, but it is not a valid reason to discard the only CSF from a neonate with vesicles and suspected CNS disease.
What the delay does affect: a modest loss of amplifiable DNA and possible bacterial overgrowth in a bloody, protein-rich specimen. What it does not do: create a false positive, and it is unlikely to produce a false negative from DNA degradation alone at this target size.
The real risk is the bloody matrix (hemoglobin, porphyrins, and a large excess of human genomic DNA), so the internal control must be evaluated and the report must state the preanalytical delay. Rejecting would delay diagnosis by a full day and risks a second lumbar puncture in a sick neonate.
2. What technical problems does the grossly bloody CSF create, and how do you handle them at the bench?
Read the worked answer
- Inhibition: heme and its degradation products inhibit Taq polymerase; human genomic DNA at high concentration competes for primers and probe and can raise background.
- Internal control is the gate: if the IC amplifies within its acceptance range, the negative/positive call stands. If the IC fails, the result is invalid, not negative.
- Mitigation if IC fails: re-extract from a larger volume with an inhibitor-removal chemistry; centrifuging the CSF and testing the supernatant (virus is largely cell-free) reduces cellular and hemoglobin content; a modest dilution may relieve inhibition at some cost in sensitivity.
- Do not pre-dilute routinely - the assay is already at a 500 copies/mL limit of detection, and dilution can push a low-positive neonatal specimen below it.
- Freeze an aliquot of the original specimen at -70 C in case repeat extraction is needed, and record specimen appearance on the report.
3. Suppose the IC passes and HSV-1/2 is not detected. How do you word the report, and would you recommend stopping acyclovir?
Read the worked answer
Report: "HSV-1/2 DNA not detected by real-time PCR. Internal control acceptable. Specimen grossly bloody (RBC 52,000/microliter) and received 17.7 hours after collection; these preanalytical factors are noted."
Do not support stopping acyclovir on this single result. CSF PCR sensitivity in neonatal HSV is high for CNS disease but is reduced in disseminated and skin-eye-mouth disease, and a single negative CSF does not exclude the diagnosis. Neonatal disease can progress despite an initially negative CSF.
Additional testing to recommend: swab of the vesicle base (highest yield), surface swabs (conjunctiva, nasopharynx, rectum), whole-blood EDTA for HSV DNA (DNAemia is common in disseminated neonatal disease), and ALT as an adjunct. Repeat lumbar puncture may be warranted if the clinical picture remains consistent.
The judgment point: a technically valid negative on a compromised specimen informs the clinician but does not carry the weight of a negative on an ideal specimen.